EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 298 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Transforming Cancer Clinical Trials for Better, Faster Results April 14, 2023 Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο January 25, 2020 FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell... January 31, 2025 Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive... July 19, 2024 Load more HOT NEWS Women in Science: Celebrating with our Women of Influence initiative Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with... What to Know About Mastectomy With Flat Closure After a Breast... Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who...
